Good news spread frequently, and scientific and technological innovation yielded fruitful results. The second batch of "Zhongguancun enterprise patents, technical standards and other support funds" recently released, Dongfang Baitai stood out. It was recognized as a high-value invention patent for Zhongguancun technology-based SMEs. This is the growth witness of Dongfang Baitai's innovative development. This is also a reflection of its responsibility to actively implement the ESG development concept.

Beijing Municipal Commission of Science and Technology and Zhongguancun Science and Technology Park Management Committee released the second batch of enterprises with "Zhongguancun enterprise patents, technical standards and other supporting funds". A total of 64 enterprises in Beijing were selected. The aim is to promote the development of the city's "high-tech" industries and high-value invention patents with medical technology-based small and medium-sized enterprises in Zhongguancun Demonstration Zone. With excellent innovation achievements, Dongfang Baitai's independently developed high-value invention patent, "a fusion protein of Exendin-4 and its analogues" (ZL201010205166.9), was successfully selected and won a support fund of 500000 yuan.

Dongfang Baitai fully implements the patented technology of "a fusion protein of Exendin-4 and its analogues". Exendin-4 Fc fusion protein (JY09), a new generation of GLP-1 analogues, was developed by using global leading gene recombination, mammalian cell expression and other technical means. For the treatment of type 2 diabetes. JY09 is the first domestic and internationally leading variety with independent intellectual property rights. It is a "triple" project of the national major new drug innovation project. It is the first new long-acting GLP-1 analog to apply for clinical trial in China.

JY09 is an Exendin-4 Fc fusion protein independently developed by the company for long-term treatment of type 2 diabetes. It is expected that the drug can be administered once every two weeks, which is the world's leading level. It breaks through the technical bottleneck that traditional GLP-1 receptor agonists need to be injected frequently. From three injections a day to one administration every 14 days, it greatly alleviates the pain and inconvenience of patients. JY09 can repair the function of islet cells, which to some extent makes it possible to cure type 2 diabetes. It can steadily control the blood sugar level of patients, reduce the risk of hypoglycemia, and improve the safety of drug use. At the same time, it can reduce cardiovascular risk and benefit the kidneys. It can reduce appetite, prolong gastric emptying time and control the weight of patients. JY09 is conducting a multicenter phase II clinical study and is expected to apply for listing in 2024.

By 2021, Dongfang Baitai has applied for 109 invention patents in total. Among them, there are 49 domestic patents and 60 foreign patents.
With the continuous innovation of the company, Dongfang Baitai's high value patents continue to be distributed. A fusion protein of Exendin-4 and its analogues, an improved monoclonal antibody against VEGFR-2, a bispecific antibody against EGFR and anti-CD3 and its application, a monoclonal antibody against PD-1 and its obtaining method, and a monoclonal antibody against PCSK9 have been obtained "And many other invention patents. At the same time, international patents are distributed. In the implementation of patent technology, the indications of patented products cover many high incidence diseases, such as malignant tumors, diabetes, rheumatoid arthritis, ophthalmic diseases, asthma, and so on. They have made certain contributions in the field of biomedicine.

Dongfang Baitai will take this opportunity to further strengthen its independent knowledge innovation ability and achievements transformation. The research results are widely used in the treatment and prevention of major diseases. In the future, Dongfang Baitai will gather innovative development momentum, fully accumulate and give play to the advantages of independent intellectual property rights. We will strengthen the company's R&D investment, and actively play the role of invention patents in supporting the company's main business. We will continue to promote the development of the biomedical industry to better benefit mankind and create health.